Vir Biotechnology IPO

Vir Biotechnology is a clinical-stage biotechnology company focused on developing treatments for serious infectious diseases, with particular expertise in viral infections including hepatitis B, influenza, and COVID-19. The company's approach combines cutting-edge immunology, technology platforms, and partnerships with leading academic institutions and pharmaceutical companies. Vir's technology platforms include T cell and B cell engineering, antibody discovery and engineering, and viral vectors for vaccine development.

Vir gained significant attention during the COVID-19 pandemic through its development of sotrovimab, a monoclonal antibody treatment for COVID-19 developed in partnership with GSK. While regulatory authorizations for sotrovimab were later withdrawn due to reduced efficacy against newer variants, the partnership demonstrated Vir's capability to rapidly develop and commercialize treatments for emerging infectious diseases. The company continues to advance its pipeline of treatments for chronic hepatitis B, seasonal and pandemic influenza, and other serious viral infections, positioning itself as a key player in the infectious disease space with multiple potential first-in-class therapies in development.